JP2007515413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007515413A5 JP2007515413A5 JP2006544085A JP2006544085A JP2007515413A5 JP 2007515413 A5 JP2007515413 A5 JP 2007515413A5 JP 2006544085 A JP2006544085 A JP 2006544085A JP 2006544085 A JP2006544085 A JP 2006544085A JP 2007515413 A5 JP2007515413 A5 JP 2007515413A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- group
- composition
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 44
- 239000000203 mixture Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000002366 halogen compounds Chemical class 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004953 trihalomethyl group Chemical group 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010067807 Gingival cancer Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010024612 Lipoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 1
- 206010053648 Vascular occlusion Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 101100311214 Xenopus laevis stat3.1 gene Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- -1 alkyl aryl compound Chemical class 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000004933 in situ carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001855 preneoplastic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000021331 vascular occlusion disease Diseases 0.000 claims 1
- 0 *C(C1*)C(*)C(*#C)=NC1I Chemical compound *C(C1*)C(*)C(*#C)=NC1I 0.000 description 20
- RTHIJLAJXLSSFT-NTCAYCPXSA-N CCC(C1)C1(c1ccccc1)NC(/C(/C#N)=C/c1cccc([Br]=C)n1)=O Chemical compound CCC(C1)C1(c1ccccc1)NC(/C(/C#N)=C/c1cccc([Br]=C)n1)=O RTHIJLAJXLSSFT-NTCAYCPXSA-N 0.000 description 1
- VXRMKIVOCWHMKE-VMEIHUARSA-N CC[C@@H](c1ccccc1)NC(/C(/C#N)=C/C1=NC([Br]=C)=CCC1)=O Chemical compound CC[C@@H](c1ccccc1)NC(/C(/C#N)=C/C1=NC([Br]=C)=CCC1)=O VXRMKIVOCWHMKE-VMEIHUARSA-N 0.000 description 1
- PPOZKKRPVCVLTC-OQLLNIDSSA-N N#C/C(/C(NCc1ccccc1)=O)=C\c1cnccc1 Chemical compound N#C/C(/C(NCc1ccccc1)=O)=C\c1cnccc1 PPOZKKRPVCVLTC-OQLLNIDSSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52887703P | 2003-12-11 | 2003-12-11 | |
| US60/528,877 | 2003-12-11 | ||
| PCT/US2004/041712 WO2005058829A1 (en) | 2003-12-11 | 2004-12-13 | Compounds for treatment of cell proliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007515413A JP2007515413A (ja) | 2007-06-14 |
| JP2007515413A5 true JP2007515413A5 (https=) | 2008-02-07 |
| JP4751336B2 JP4751336B2 (ja) | 2011-08-17 |
Family
ID=34699909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006544085A Expired - Fee Related JP4751336B2 (ja) | 2003-12-11 | 2004-12-13 | 細胞増殖性疾患を治療する化合 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7745468B2 (https=) |
| EP (2) | EP1701941B1 (https=) |
| JP (1) | JP4751336B2 (https=) |
| KR (2) | KR101170655B1 (https=) |
| CN (2) | CN1894215B (https=) |
| AU (1) | AU2004298511B2 (https=) |
| BR (1) | BRPI0416981A (https=) |
| CA (1) | CA2548152C (https=) |
| DK (1) | DK1701941T3 (https=) |
| ES (1) | ES2385831T3 (https=) |
| IL (1) | IL176028A (https=) |
| MX (1) | MXPA06006460A (https=) |
| PL (1) | PL1701941T3 (https=) |
| PT (1) | PT1701941E (https=) |
| SI (1) | SI1701941T1 (https=) |
| WO (1) | WO2005058829A1 (https=) |
| ZA (1) | ZA200604682B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06006460A (es) | 2003-12-11 | 2006-08-23 | Univ Texas | Compuestos para el tratamiento de enfermedades proliferativas celulares. |
| ZA200803226B (en) | 2005-10-13 | 2009-11-25 | Orchid Res Lab Ltd | Heterocyclic Compounds as Pstat3/IL-6 Inhibitors |
| RU2456265C2 (ru) * | 2006-03-31 | 2012-07-20 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам |
| US20100292229A1 (en) * | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| AU2007322033B2 (en) | 2006-11-20 | 2013-07-11 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
| US20080167277A1 (en) * | 2006-12-29 | 2008-07-10 | Charles Conrad | Methods of treating skin disorders with caffeic acid analogs |
| WO2008121858A1 (en) * | 2007-03-28 | 2008-10-09 | Board Of Regents, The University Of Texas System | Small molecule inhibitors for immune modulation |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| AU2009268841B2 (en) | 2008-07-08 | 2014-02-06 | Board Of Regents, The University Of Texas System | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS) |
| US8450337B2 (en) * | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| CA2738786C (en) | 2008-09-30 | 2017-12-19 | Mallinckrodt Inc. | A version of fdg detectable by single-photon emission computed tomography |
| WO2010081158A2 (en) * | 2009-01-12 | 2010-07-15 | The Board Of Regents Of The University Of Texas System | Blood test for the detection of cancer |
| JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| MX2012004363A (es) | 2009-10-16 | 2012-05-22 | Bayer Cropscience Ag | Aminopropenoatos como fungicidas. |
| WO2011069141A2 (en) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| EP2544686A4 (en) | 2010-02-05 | 2013-06-26 | Whitehead Biomedical Inst | COMBINATION PROCEDURE FOR THE TREATMENT OF A DISEASE |
| ES2987670T3 (es) | 2010-03-19 | 2024-11-15 | 1Globe Biomedical Co Ltd | Métodos novedosos para actuar sobre células madre cancerosas |
| WO2012040527A2 (en) * | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| EP2510787A1 (en) | 2011-04-15 | 2012-10-17 | Bayer Cropscience AG | Propenoates as fungicides |
| CN103619805A (zh) | 2011-05-27 | 2014-03-05 | 国立大学法人德岛大学 | 苄胺衍生物 |
| EP2731493B1 (en) | 2011-07-11 | 2015-07-01 | The Regents of The University of Michigan | Multimodality left atrial appendage occlusion device |
| CN110003104A (zh) * | 2012-05-25 | 2019-07-12 | 多伦多大学管理委员会 | 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 |
| US20150209406A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| CA2908380A1 (en) | 2013-04-09 | 2014-10-16 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2015002766A1 (en) | 2013-07-02 | 2015-01-08 | Nikolai Khodarev | Anti-tumor therapy |
| JP2016537316A (ja) * | 2013-10-10 | 2016-12-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| US11370823B2 (en) | 2014-10-29 | 2022-06-28 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
| KR20180069782A (ko) | 2015-08-03 | 2018-06-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 하전 이온 채널 블록커 및 이용 방법 |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| TWI846678B (zh) * | 2017-11-10 | 2024-07-01 | 美國德州系統大學評議委員會 | 咖啡酸衍生物及其用途 |
| WO2019148067A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss |
| AU2020235888A1 (en) | 2019-03-11 | 2021-09-30 | Nocion Therapeutics, Inc. | Charged ION channel blockers and methods for use |
| MX2021010869A (es) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso. |
| US10934263B2 (en) | 2019-03-11 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2020206105A1 (en) * | 2019-04-02 | 2020-10-08 | Board Of Regents, The University Of Texas System | Combinations of transcription inhibitors and immune checkpoint inhibitors for treatment of disease |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| CN114828845A (zh) | 2019-11-06 | 2022-07-29 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN119118953A (zh) | 2020-03-11 | 2024-12-13 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| CN115381822A (zh) * | 2022-05-11 | 2022-11-25 | 暨南大学附属第一医院（广州华侨医院） | 一种基于激活免疫应答治疗肺癌的药物及制药应用 |
| KR102811597B1 (ko) * | 2022-06-22 | 2025-05-22 | 한국생명공학연구원 | 신규한 신남아마이드 유도체 및 이의 용도 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2555789A1 (de) * | 1975-12-11 | 1977-07-07 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| FR2629455B1 (fr) * | 1988-03-29 | 1991-09-27 | Rhone Poulenc Agrochimie | Derives de 2-(3-pyridinyl)3-(phenoxy) propanenitrile |
| GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
| WO1991016305A1 (en) | 1990-04-16 | 1991-10-31 | Rhone-Poulenc Rorer International (Holdings), Inc. | Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| CA2080554A1 (en) * | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
| JPH05301838A (ja) * | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| CA2092017A1 (en) | 1992-03-26 | 1993-09-27 | Tameo Iwasaki | Butadiene derivatives and process for preparing the same |
| US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
| JPH06247850A (ja) | 1993-02-24 | 1994-09-06 | Suntory Ltd | １２−リポキシゲナーゼ阻害剤 |
| EP0711372B1 (en) | 1993-07-27 | 1998-11-04 | The University Of Birmingham | Improvements in or relating to pavements |
| GB9322781D0 (en) * | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
| IL107736A (en) | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
| IL112205A0 (en) | 1994-01-06 | 1995-03-15 | Res Dev Foundation | Curcumin, analogues of curcumin and novel uses thereof |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
| CA2187752A1 (en) | 1994-04-22 | 1995-11-02 | Chaim M. Roifman | Use of benzylidene-malononitrile derivates for the treatment of leukemia |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| IL119069A0 (en) * | 1996-08-14 | 1996-11-14 | Mor Research Applic Ltd | Pharmaceutical composition comprising tyrphostins |
| US5854285A (en) | 1997-04-03 | 1998-12-29 | Natpro, Inc. | Protein kinase inhibitor |
| US6420338B1 (en) | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| US6313153B1 (en) | 1997-07-25 | 2001-11-06 | Tsumura & Co. | Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives |
| US6225346B1 (en) | 1997-10-24 | 2001-05-01 | Sugen, Inc. | Tyrphostin like compounds |
| WO2000052062A1 (fr) | 1999-03-04 | 2000-09-08 | Riken | Composition de catalyseur |
| US20020045191A1 (en) | 2000-09-15 | 2002-04-18 | Schneider Robert J. | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| JP2003119169A (ja) | 2001-07-30 | 2003-04-23 | Shigetoshi Kadota | 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物 |
| US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| EP1457205A4 (en) | 2001-11-30 | 2006-07-05 | Santen Pharmaceutical Co Ltd | INHIBITOR OF ANGIOGENESIS |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| US7045551B2 (en) | 2002-11-22 | 2006-05-16 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
| KR20050055479A (ko) | 2003-12-08 | 2005-06-13 | 김철호 | 카페인산 또는 카페인산 페네틸에스테르를 유효성분으로하는 ｍｍｐ-9 억제제 |
| MXPA06006460A (es) | 2003-12-11 | 2006-08-23 | Univ Texas | Compuestos para el tratamiento de enfermedades proliferativas celulares. |
| RU2456265C2 (ru) * | 2006-03-31 | 2012-07-20 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам |
| US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| US8741342B2 (en) * | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
-
2004
- 2004-12-13 MX MXPA06006460A patent/MXPA06006460A/es active IP Right Grant
- 2004-12-13 EP EP04813958A patent/EP1701941B1/en not_active Expired - Lifetime
- 2004-12-13 WO PCT/US2004/041712 patent/WO2005058829A1/en not_active Ceased
- 2004-12-13 SI SI200431908T patent/SI1701941T1/sl unknown
- 2004-12-13 BR BRPI0416981-6A patent/BRPI0416981A/pt not_active IP Right Cessation
- 2004-12-13 CN CN2004800370450A patent/CN1894215B/zh not_active Expired - Fee Related
- 2004-12-13 KR KR1020067013861A patent/KR101170655B1/ko not_active Expired - Fee Related
- 2004-12-13 PL PL04813958T patent/PL1701941T3/pl unknown
- 2004-12-13 EP EP12167605.0A patent/EP2487156B1/en not_active Expired - Lifetime
- 2004-12-13 CA CA2548152A patent/CA2548152C/en not_active Expired - Lifetime
- 2004-12-13 CN CN2012100233394A patent/CN102603565A/zh active Pending
- 2004-12-13 AU AU2004298511A patent/AU2004298511B2/en not_active Ceased
- 2004-12-13 DK DK04813958.8T patent/DK1701941T3/da active
- 2004-12-13 ES ES04813958T patent/ES2385831T3/es not_active Expired - Lifetime
- 2004-12-13 US US11/010,834 patent/US7745468B2/en active Active
- 2004-12-13 PT PT04813958T patent/PT1701941E/pt unknown
- 2004-12-13 KR KR1020117027869A patent/KR101218633B1/ko not_active Expired - Fee Related
- 2004-12-13 JP JP2006544085A patent/JP4751336B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-30 IL IL176028A patent/IL176028A/en active IP Right Review Request
- 2006-06-07 ZA ZA2006/04682A patent/ZA200604682B/en unknown
-
2010
- 2010-06-28 US US12/824,901 patent/US8119827B2/en not_active Expired - Fee Related
-
2012
- 2012-01-13 US US13/350,637 patent/US8648102B2/en not_active Expired - Fee Related
-
2014
- 2014-01-03 US US14/147,089 patent/US9096499B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007515413A5 (https=) | ||
| EP2253625B1 (en) | Pyridazinones, the preparation and the use thereof | |
| JP2018138577A5 (https=) | ||
| JP2008528467A5 (https=) | ||
| RU2008143237A (ru) | Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам | |
| JP2008521928A5 (https=) | ||
| JP2010518110A5 (https=) | ||
| JP2013522292A5 (https=) | ||
| JP2009513703A5 (https=) | ||
| JP2020517616A5 (https=) | ||
| JP2011527666A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| CA2480356A1 (en) | Benzamide derivatives useful as histone deacetylase inhibitors | |
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| RU2016136823A (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| JP2020535168A5 (https=) | ||
| JP2011511095A5 (https=) | ||
| CN105218532B (zh) | 苯并三氮唑类化合物、制备方法和其医药用途 | |
| JP2012509265A5 (https=) | ||
| JP2014504646A5 (https=) | ||
| ES2833459T3 (es) | Compuestos que inhiben la ARN polimerasa, composiciones que incluyen dichos compuestos y su uso | |
| JP2007523177A5 (https=) | ||
| JP2022071077A5 (https=) | ||
| JP2014530811A (ja) | 有機ニトロチオエーテル化合物およびその医療用途 | |
| JP2011513419A5 (https=) |